Study of the polymorphisms of cyclooxygenase‑2 (‑765G>C) and 5‑lipoxygenase (1708G>A) in patients with colorectal cancer

Pimenta,Célia Aparecida Marques; Latini,Flavia Roche Moreira; De Lima,Jacqueline Miranda; Da Silva,Tiago Donizetti; Felipe,Aledson Vitor; De Lima Pazine,Vanessa Maria; Forones,Nora Manoukian

doi:10.3892/ol.2013.1732

Study of the polymorphisms of cyclooxygenase‑2 (‑765G>C) and 5‑lipoxygenase (1708G>A) in patients with colorectal cancer

Authors:
- Célia Aparecida Marques Pimenta
- Flavia Roche Moreira Latini
- Jacqueline Miranda De Lima
- Tiago Donizetti Da Silva
- Aledson Vitor Felipe
- Vanessa Maria De Lima Pazine
- Nora Manoukian Forones
View Affiliations

Affiliations: Gastroenterology Division, Federal University of São Paulo, São Paulo 04023900, Brazil
Published online on: December 5, 2013 https://doi.org/10.3892/ol.2013.1732
Pages: 513-518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the fourth most common cause of cancer‑related mortality worldwide. Genetic alterations have been associated with an increased risk of cancer and greater tumor aggressiveness. Cyclooxygenase‑2 (COX‑2) and 5‑lipoxygenase (5‑LOX) genes are important in cell cycle regulation, tumor growth and prostaglandin synthesis. The aim of the present study was to investigate the association between polymorphisms in the COX‑2 and 5‑LOX genes and the risk of CRC. A case‑control study was conducted in patients with CRC matched for gender and age to a control group. DNA was extracted from peripheral leukocytes, and the polymorphisms were analyzed by polymerase chain reaction‑restriction fragment length polymorphism and gene sequencing. A specific questionnaire was applied to evaluate smoking, excessive alcohol consumption, physical activity, non‑steroidal anti‑inflammatory drug use and meat, fiber and fat intake. A total of 185 patients with CRC and 146 controls were studied. The heterozygous GC genotype of the COX‑2 gene polymorphism was the most common in the two groups (60.0% in CRC patients and 52.7% in controls). The CC genotype was associated with an increased risk of CRC (odds ratio, 3.63; 95% confidence interval, 1.31‑10.1; P=0.013). The homozygous wild‑type genotype of the 5‑LOX gene polymorphism was detected in 72.4% of the CRC patients and in 71.2% of the control subjects. The homozygous mutant genotype (CC) of the COX‑2 gene is an independent risk factor for CRC. No association was found between 5‑LOX genotypes and CRC.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Globocan 2008: Cancer incidence and mortality worldwide. IARC CancerBase No. 10 Lyon, France: 2010, http://globocan.iarc.fr. Accessed August 31, 2011
2	Estimates 2012: Cancer incidence in Brazil. INCA (National Cancer Institute); Rio de Janiero, Brazil: pp. 34–35. 2012
3	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
4	Fleisher AS, Esteller M, Harpaz N, et al: Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 60:4864–4868. 2000.
5	Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D and Darnell J: Genetic analysis in molecular biology. Cal and Molecular Biology. Nader HB: Rio de Janeiro: Revinter; pp. 255–293. 2002
6	Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, Büchler MW, Pour PM and Adrian TE: 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 161:421–428. 2002. View Article : Google Scholar
7	Williams CS, Mann M and DuBois RN: The role of cyclooxygense in inflammation, cancer, and development. Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
8	Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC and Kelloff GJ: Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemol Biomarkers Prev. 8:467–483. 1999.PubMed/NCBI
9	Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE and Laurent GJ: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 22:1631–1636. 2002. View Article : Google Scholar : PubMed/NCBI
10	Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadluabar FF and Lin D: Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 129:565–576. 2005.PubMed/NCBI
11	Borgeat P, Hamberg M and Samuelsson B: Transformation of arachidonic acid homo-gamma-linoleic acid by rabbit polymorphonuclear leuckocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem. 251:7816–7820. 1976.
12	Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O’Byrne K, Nie D and Honn KV: Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 26:503–524. 2007. View Article : Google Scholar : PubMed/NCBI
13	Goel A and Boland CR: Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol. 26:47–52. 2010. View Article : Google Scholar : PubMed/NCBI
14	Fitzpatrick FA: Inflammation, carcinogenesis, and cancer. Int Immunopharmacol. 1:1651–1667. 2001. View Article : Google Scholar : PubMed/NCBI
15	Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G and Anton-Culver H: Meat consumption, nonsteroidal anti-inflamatory drug use, and mortality among colorectal cancer patients in the California Teachers Study. Cancer Prev Res. 3:865–875. 2010. View Article : Google Scholar : PubMed/NCBI
16	Demarzo MM, Martins LV, Fernandes CR, Herrero FA, Perez SE, Turatti A and Garcia SB: Exercise reduces inflammation and cell proliferation in rat colon carcinogenesis. Med Sci Sports Exerc. 40:618–621. 2008. View Article : Google Scholar : PubMed/NCBI
17	Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 348:891–898. 2003. View Article : Google Scholar : PubMed/NCBI
18	Pandey S, Mittal RD, Srivastava M, Srivastava K and Mittal B: Cyclooxygenase-2 gene polymorphisms and risk of cervical cancer in a North Indian population. Int J Gynecol Cancer. 20:625–630. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hirano T: Alcohol consumption and oxidative DNA damage. Int J Environ Res Public Health. 8:2895–2906. 2011. View Article : Google Scholar : PubMed/NCBI
20	Hoff JH, te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM and Peters WH: COX-2 polymorphisms −765G-->C and −1195A-->G and colorectal cancer risk. World J Gastroenterol. 15:4561–4565. 2009.
21	Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, Luo Y and Zhang X: Cyclooxygenase 2 polymorphism and colorectal cancer: −765G>C variant modifies risk associated with smoking and body mass index. World J Gastroenterol. 14:1785–1789. 2008.
22	Wang CH, Wu KH, Yang YL, Peng CT, Wang RF, Tsai CW, Tsai RY, Lin DT, Tsai FJ and Bau DT: Association study of cyclooxygenase 2 single nucleotide polymorphisms and childhood acute lymphoblastic leukemia in Taiwan. Anticancer Res. 30:3649–3653. 2010.PubMed/NCBI
23	Gangwar R, Mandhani A, Mittal RD and Pradesh U: Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery. 149:126–134. 2011. View Article : Google Scholar : PubMed/NCBI
24	Piranda DN, Festa-Vasconcellos JS, Amaral LM, Bergmann A and Vianna-Jorge R: Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer. 10:6132010. View Article : Google Scholar : PubMed/NCBI
25	Liang Y, Liu JL, Wu Y, Zhang ZY and Wu R: Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tohoku J Exp Med. 223:137–144. 2011. View Article : Google Scholar : PubMed/NCBI
26	Biramijamal F, Basatvat S, Hossein-Nezhad A, Soltani MS, Akbari Noghabi K, Irvanloo G and Shamimi K: Association of COX-2 promoter polymorphism with gastrointestinal tract cancer in Iran. Biochem Genet. 48:915–923. 2010. View Article : Google Scholar : PubMed/NCBI
27	Akkız H, Bayram SI, Bekar A, Akgöllü E and Ülger Y: Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem. 347:201–208. 2011.PubMed/NCBI
28	Sitarz R, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ and Milne AN: The COX-2 promoter polymorphism −765 G>C is associated with early-onset, conventional and stump gastric cancers. Mod Pathol. 21:685–690. 2008.
29	Kristinsson JO, van Westerveld P, te Morsche RH, Roelofs HM, Wobbes T, Witteman BJ, Tan AC, van Oijen MG, Jansen JB and Peters WH: Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol. 15:3493–3497. 2009. View Article : Google Scholar : PubMed/NCBI
30	Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB and Manni JJ: COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck. 31:938–943. 2009. View Article : Google Scholar : PubMed/NCBI
31	In KH, Asano K, Beier D, Grobholz J, et al: Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcriptions. J Clin Invest. 99:1130–1137. 1997. View Article : Google Scholar
32	Jiang WG, Douglas-Jones A and Mansel RE: Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids. 69:275–281. 2003. View Article : Google Scholar : PubMed/NCBI
33	Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, Yasuno M, Enomoto M and Sugihara K: Expression of 5-Lipoxygenase in human colorectal cancer. World J Gastroenterol. 39:6355–6360. 2006.PubMed/NCBI
34	Wang J, John EM and Ingles SA: 5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic acid, and risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 17:2748–2754. 2008. View Article : Google Scholar : PubMed/NCBI
35	Shen M, Vermeulen R, Rajaraman P, Menashe I, He X, Chapman RS, Yeager M, Thomas G, Burdett L, Hutchinson A, Yuenger J, Chanock S and Lan Q: Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. Environ Mol Mutagen. 50:285–290. 2009. View Article : Google Scholar : PubMed/NCBI